Section Arrow
AKTX.NASDAQ
- Akari Therapeutics plc
Quotes are at least 15-min delayed:2025/07/15 18:29 EDT
After Hours
Last
 1.1
+0.0102 (+0.94%)
Bid
1.08
Ask
1.15
High 1.1 
Low 1.09 
Volume 52 
Regular Hours
Last
 1.0898
-0.0102 (-0.93%)
Day High 
1.11 
Prev. Close
1.1 
1-M High
1.2486 
Volume 
17.59K 
Bid
1.08
Ask
1.15
Day Low
1.08 
Open
1.11 
1-M Low
1.09 
Market Cap 
35.39M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1.14 
20-SMA 1.15 
50-SMA 1.25 
52-W High 4.4 
52-W Low 0.85 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
--/-0.40
Enterprise Value
35.39M
Balance Sheet
Book Value Per Share
0.68
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
KAPAKairos Pharma Ltd.1.17+0.4849+70.78%-- 
After Hours 0.9614 -0.2086 -17.83%
NCNANuCana plc0.0502+0.0043+9.37%-- 
After Hours 0.0503 +0.0001 +0.20%
PLRZPolyrizon Ltd1.04+0.3579+52.47%-- 
After Hours 0.941 -0.099 -9.52%
CYCCCyclacel Pharmaceuticals Inc12.33+9.02+272.51%0.08PE
After Hours 8.2 -4.13 -33.50%
IOVAIovance Biotherapeutics1.94-0.07-3.48%-- 
After Hours 1.8982 -0.0418 -2.15%
Quotes are at least 15-min delayed:2025/07/15 18:29 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.